Strattera is a selective norepinephrine reuptake inhibitor (SNRI). It has a narrow therapeutic window and is generally well-tolerated. Patients are usually well tolerated, with most being well controlled with a dose of 2 mg/kg/day. No serious side effects have been reported. However, there are some reports of neuropsychiatric adverse reactions including somnolence, dizziness, and tingling in some patients, particularly in elderly. In this article, we will provide an overview of these events and review the literature. We will also discuss possible management strategies and potential risks of Strattera.
Strattera (atomolob 20, Strattera R, Strattera) is an effective drug for the treatment of ADHD. Atomolob 20 and atomolob 40 are both selective norepinephrine reuptake inhibitors []. In contrast, atomolob 40 is not an atypical norepinephrine reuptake inhibitor but it has a narrow therapeutic window []. It has a narrow therapeutic window and is generally well-tolerated []. However, there are reports of neuropsychiatric adverse reactions such as somnolence and tingling in some patients []. It is generally well tolerated and has been associated with a small risk of somnolence in children [, ]. There are some reports of drug-related adverse reactions including somnolence, tingling, and dizziness in some patients. Although these events were not reported in the literature, there is evidence from other studies that Strattera may have neuropsychiatric effects. We reviewed the literature and review the available evidence on Strattera, including case reports, open trials, and reviews [].
Strattera is an atypical norepinephrine reuptake inhibitor that has a narrow therapeutic window and is generally well-tolerated. Atomolob 40 and atomolob 20 are both selective norepinephrine reuptake inhibitors. Strattera is approved for the treatment of ADHD in both adults and children. Atomolob 40 is not an atypical norepinephrine reuptake inhibitor but it has a narrow therapeutic window and is generally well-tolerated. Atomolob 20 is not an atypical norepinephrine reuptake inhibitor but it has a narrow therapeutic window and is generally well-tolerated. Strattera is approved for the treatment of ADHD in adults.
The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser.For the best experience on our site, be sure to turn on Javascript in your browser.
Common Brand Name(s): MAOIR
SKUStrattera-10-MG-Oral-Tablet
Atom of One Pill.
20-50 mg/day For Intensity.
-Adults:
Adolescents:
These areuations depend on the patient:
Onset of action:
: "treat" as an adjunct to stimulants to lower ADHD symptoms (e.g. sleep, irritability, anxiety).Adults" may be used for short-term treatment. The choice of medication should be based on several factors, including (i) the patient's age, (ii) the severity of symptoms (e.g. level of focus, (iii) the preference (e.g. preference for a short-term treatment or ER use), (iv) the preference (e.g. preference for a long-term treatment) and (v) the experience of the person taking the medication. (i) The choice of medication should be based on the patient's age, (ii) the severity of symptoms (e.g. preference for a short-term treatment or ER use), (v) the preference (i) of the person taking the medication and (v) the experience of the person using the medication. (i) There are no data on the long-term efficacy and safety of medication (i.e. no new side effects, no worsening of symptoms or new drug interactions) in children and adolescents with ADHD.
The choice of medication should be based on the patient's age, (i) the severity of symptoms (e.g. level of focus, (ii) the preference (i) of the person taking the medication and (v) the experience of the person using the medication. (i) The person taking the medication should be managed in a secure and discreet environment (e.g. classroom, classroom with full safety precautions,/or patient support groups/integrated medical/lifestyle). (ii) The medication should be taken exactly as prescribed by the clinician and without any additional equipment or treatment.
Adolescents (seven to nine years of age): (i) Adolescents (seven to nine years) may take, either daily or over the counter (OTC) as needed, with or without food.
Adult:Adults: 40 mg/day
40 mg/day
ADULTS:Adolescents (seven to nine years): (i) Take 100 mg/day, not more than twice a day, with food (no additional food or drug added), with or without food.
HIGH-ACCUTIENTS:Adolescents (seven to nine years): (i) Have been prescribed 40 mg/day for ADHD treatment. (ii) Are on a stimulant or non-stimulant treatment (e.g. methylphenidate, amphetamine, placebrel).
Patients with a predisposition to multiple sclerosis (e.g.
Atomoxetine (Strattera®) is used to treat adults and children over 12. Symptoms of elevated, including difficulty swallowing, agitation, confusion, and headache, are usually improved within a few days, but some side effects may persist. Symptoms may include:
Atomoxetine may be used for some conditions. If you are planning to have surgery or have an emergency medical treatment, make sure to complete the entire prescription, even if you feel better.
This medicine is not suitable for infants under 12 years of age. This medicine is not approved for children under 12 years of age.
Atomoxetine should be taken exactly as prescribed by your doctor. The recommended starting dose is 50 mg once daily, taken as needed, to achieve the best results. This may be increased to 100 mg once daily, as needed. It is important to take this medicine regularly, and at the same time each day, to avoid missing a dose. If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next one at your regular time. Do not take two doses to make up for a missed dose.
This medication is not suitable for infants under 12 years of age. It is not recommended for use in children under the age of 18 years.
Consult your doctor before taking Strattera if you have any of the following conditions:
Some people may experience symptoms of an allergic reaction, including rash, itching/swelling (especially of the face/tongue/throat), trouble breathing, and hives, with an increase in frequency or intensity. To avoid these symptoms, inform your doctor about your medical history.
If the rash occurs in your child, your doctor will determine the appropriate dose and frequency for you. Do not take a higher dose than the prescribed one without doctor's advice.
This is a medicine. Keep your doctor informed if you have an allergy to Atomoxetine or any other medication. You may need a lower dose if you have a history of allergic reactions. Be careful with drugs, including atomoxetine, because you may get the same reaction with higher doses.
Talk to your doctor before taking Strattera if you are pregnant, planning to become pregnant, or breastfeeding. Strattera passes into your breast milk and can be dangerous if you breastfeed while taking it. Your doctor will discuss the best course of action for you.
Your doctor will discuss the most effective treatment for you. Strattera is not recommended for use in children under 12 years of age.
This medication may reduce blood flow to the nerves and kidneys. Do not take this medication with any other medication (including non-medication medications), as atomoxetine may cause a temporary loss of vision.
Attention deficit hyperactivity disorder (ADHD) is a chronic and disabling neurodevelopmental disorder (NPD). The most common of which is ADHD, approximately 1–5% of children and adolescents experience severe ADHD symptoms, with the majority of cases present in childhood (0.1%) or adolescence (0.03%).
ADHD is a common and often disabling neurodevelopmental disorder (NPD). It is a chronic and multifactorial condition characterized by the development and progression of multiple behavioral and neurobiological patterns (see ). The most common symptoms of ADHD are the ability to get or maintain an active social environment (eg, socializing, social relationships, and/or environmental influences).
The pathophysiology of ADHD is complex and involves the development of various neurochemical, biological, and behavioral effects (see for more detailed descriptions of specific neurochemical pathways). The dysregulation of the prefrontal cortex (PFC) and the presence of prefrontal cortical areas (PFCa) in the brain, particularly in the prefrontal cortex and the anterior cingulate cortex (ACC) have been implicated in the pathophysiology of ADHD (, ).Neurological abnormalities in the prefrontal cortex and ACC are associated with ADHD (,, ;,, ; ). These abnormalities can be associated with hyperactivity (, ) or depression (,, ).
The central executive functioning of ADHD is affected by a variety of neurological and neurobiological factors (see ). The frontal lobe and temporal lobe, or co-occurring areas, of the brain are responsible for many of the behavioral and neurobiological effects of ADHD. In ADHD, the prefrontal cortex, the core of the brain, is responsible for executive functioning and cognitive functioning, while the temporal lobe, or the temporal lobe center of the brain, is involved in attention, impulse control, and memory, and may be responsible for both, and.
The dysregulation of the executive functioning of ADHD may also occur in multiple brain regions. For example, patients with ADHD exhibit different neural connections to the prefrontal cortex and the temporal lobe. In the prefrontal cortex, the prefrontal cortex is implicated in executive functioning (; ; ). In the temporal lobe, the temporal lobe is implicated in executive functioning (; ). In the frontal lobe, the frontal lobe is involved in executive functioning (; ; ). Patients with ADHD have also demonstrated abnormalities in the temporal lobe and the frontal lobe, but have not shown differences in executive functioning between the two conditions (; ). In addition, the anterior cingulate cortex has a deficit in executive functioning in patients with ADHD (; ).
The frontal lobe is also involved in cognitive function (; ; ; ). The frontal lobe is also involved in cognitive function, and is involved in executive functioning in patients with ADHD (,, ; ; ). Patients with ADHD have also demonstrated abnormalities in executive functioning (; ; ; ; ).
The temporal lobe is involved in executive functioning, and is involved in cognitive function in patients with ADHD (; ; ). Patients with ADHD also have been shown to have higher levels of executive functioning (; ; ; ).
The frontal lobe, or co-occurring areas, of the brain, is involved in many cognitive functions, including attention, impulse control, and memory. In patients with ADHD, the frontal lobe has a deficit in executive functioning and may be involved in cognitive functioning, but also in attention, impulse control, and memory.
The prefrontal cortex, or PFC, is one of the core structures of the brain involved in executive functioning and executive performance. It is involved in executive functioning in patients with ADHD (; ). Patients with ADHD have shown higher levels of executive functioning than other groups of patients (; ; ).
The PFC has an important role in executive functioning in patients with ADHD. It is involved in cognitive and attention, and is involved in executive and attention and memory (; ; ). Patients with ADHD have also shown higher levels of executive functioning than other groups of patients (; ; ).
In patients with ADHD, the PFC is involved in executive functioning and executive performance (; ). Patients with ADHD have shown higher levels of executive functioning than other groups of patients (; ).
In patients with ADHD, the PFC is involved in cognitive and attention, and is involved in executive and attention and memory (; ). Patients with ADHD have also shown higher levels of executive functioning than other groups of patients (; ).
The frontal lobe is involved in executive functioning in patients with ADHD (; ). The frontal lobe is involved in cognitive and attention, and is involved in executive and attention and memory (; ).
Stade de France Pharmacy